CLINICAL_TRIALS
trial_result
· 2019-02-08
Clinical Trial Update: The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease [Phase 3]
Summary
This document reports the completion and posting of results from a Phase 3 trial evaluating GLP-1 receptor agonism for diabetic kidney disease.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Karl Neff | Conditions: Diabetic Kidney Disease | Phase 3 | Status: COMPLETED | Results posted: 2019-02-08